Non-self-injection breast augmentation material is mainly “hydrophilic polyacrylamide gel” (“Omedin” or “Ingelfahrer”), because it can be decomposed into dramin monomer molecules in the human body On April 30, 2006, the State Food and Drug Administration issued a notice that the polyacrylamide hydrogel for injection (trade names: Ingelfahrer and Omedine) had been used in the process of suspicious adverse events and patient complaints. , after evaluation of the product can not guarantee the safety in use in the market, according to the “supervision and management of medical devices regulations” Article 32 and “medical device registration management methods” Article 44 of the provisions of the comprehensive stop production, sales and use of polyacrylamide hydrogel (for injection). Complications: 1, local hard nodules, gel islands. Breast tissue, subcutaneous can appear hard nodules, making the breast feel poor, breast lumps difficult to identify when self-examination. 2. The injected material is diffuse and has the phenomenon of wandering. The material has a certain mobility, so the injected material will “flow” under the skin to the abdomen due to gravity and connect with the breast injection gap, resulting in strange breast shape. It will also be everywhere in the body, making hard lumps everywhere, and some people even have them on their feet. 3. Infection. Lactation leads to severe mastitis, or acute infection causing local redness, swelling and pain, ulceration and pus. 4.Aseptic inflammation. As the injection material interferes with the function of a person’s own immune system, it can manifest itself as a long-term recurrent low fever. 5.Kidney infringement, toxic damage to nerve organs. 6.It may cause breast cancer. 7, local hidden pain.